Related Experiment Videos
[Studies on oxacephems, an artificial type of beta-lactam antibiotics]
W Nagata1, M Narisada, M Yoshioka
1Shionogi Research Laboratories, Shionogi & Co., Ltd., Osaka, Japan.
Abstract:
A pioneering work in the field of oxacephem antibiotics which had been carried out in our research laboratories is reviewed. Our research of beta-lactam antibiotics was started in 1974 with the policy to make chemical modification at the nuclei but not the side chain of the existing beta-lactam antibiotics, with an expectation to discover a new type of antibiotics. After the success in establishing an efficient synthetic method for 3'-norcephalosporin, we started oxacephem research in 1975. We succeeded in developing three synthetic methods starting from penicillins which efficiently served to prepare numerous oxacephem (1-oxa-1-dethia-cephalosporin) derivatives. It turned out that the oxacephem nucleus was much more distorted with an increased ring strain, resulting in reduction of the beta-lactam amide resonance to a greater extent than the cephalosporin nucleus. This physicochemical properties conferred an increased chemical reactivity on the nucleus as evidenced by an increased hydrolysis rate as compared with the corresponding 1-thia counterpart. This increased chemical reactivity coupled with the reduced hydrophobicity of the oxacephem nucleus as evidenced by the lower distribution constant in a water-octanol system, characterized unique biological properties of oxacephem derivatives. These include (1) 2-16 times increase in antibacterial activity with emphasis against gram-negative bacteria; (2) increased protecting effect in vivo parallel to the increased in vitro activity; (3) reduction of the stability to beta-lactamases leading to decreased antibacterial activity against the beta-lactamase producing strains; (4) 1.6-3.2 times increase in penetrability through the outer membrane of certain gram-negative bacteria, the increase being due to the increased hydrophilicity of the oxacephem nucleus; (5) remarkably reduced binding to human serum albumin improving the efficacy of the oxacephems in the blood; (6) a remarkable change in the excretion pattern, i.e. recovery in the bile reduced and that in the urine increased. These biological characteristics are generally favorable for antibacterial agents against pathogenic diseases except for the reduced stability to beta-lactamases. This unfavorable property of the oxacephem nucleus was the only barrier for developing a new agent of the oxacephem nucleus. However, this problem was relatively easily solved by introduction of (1) the methoxy group at 7 alpha and (2) appropriately alpha-substituted acyl amide chain at 7 beta; the former and the latter substituent effectively stabilized the oxacephems to various kinds of penicillinases and cephalosporinases, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)
Insights
Researchers developed novel oxacephem antibiotics by modifying beta-lactam structures. These new antibiotics show enhanced antibacterial activity, particularly against gram-negative bacteria, and improved drug efficacy.
Area of Science:
- Medicinal Chemistry
- Antibiotic Development
- Organic Synthesis
Context:
- Research focused on modifying existing beta-lactam antibiotics to discover new classes.
- Initiated in 1974, the strategy involved chemical modifications of the core structure rather than side chains.
- Oxacephem research began in 1975 following successful synthesis of 3'-norcephalosporins.
Purpose:
- To synthesize and characterize novel oxacephem (1-oxa-1-dethia-cephalosporin) derivatives.
- To investigate the physicochemical and biological properties of oxacephem antibiotics.
- To overcome limitations of existing beta-lactam antibiotics through structural innovation.
Summary:
- Developed three synthetic methods from penicillins to produce oxacephem derivatives.
- Oxacephem nucleus exhibits increased ring strain and reactivity compared to cephalosporins.
- Key properties include enhanced antibacterial activity, improved in vivo efficacy, increased outer membrane penetration, reduced serum albumin binding, and altered excretion patterns.
- Reduced stability to beta-lactamases was a challenge, addressed by introducing methoxy groups and specific acyl amide side chains.
Impact:
- Oxacephem derivatives demonstrate 2-16 fold increase in antibacterial activity, especially against gram-negative bacteria.
- Improved pharmacokinetic properties, including enhanced penetration and reduced protein binding, leading to better therapeutic efficacy.
- Structural modifications successfully stabilized oxacephems against beta-lactamases, overcoming a major hurdle for clinical development.